TLRY

Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.

Tilray (NASDAQ: TLRY) reported Q3 sales of $51.41 million. Earnings fell to a loss of $31.35 million, resulting in a 57.91% decrease from last quarter. In Q2, Tilray brought in $50.41 million in sales but lost $74.49 million in earnings.Why ROCE Is Significant Changes in earnings and sales indicate shifts in Tilray's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Tilray posted an ROCE of -0.17%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on TLRYROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Tilray is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In Tilray's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q3 Earnings Insight Tilray reported Q3 earnings per share at $-0.02/share, which beat analyst predictions of $-0.21/share.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Tuesday's Pre-Market Session * Benzinga's Top Upgrades, Downgrades For November 16, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Aphria (APHA) has closed its takeover of privately held Sweetwater Brewing Company, one of the largest independent craft brewers, for ~$300M. The deal was announced on November 4.Shares are up 7% premarket

Aurora Cannabis (ACB) has entered into a strategic Supply Agreement with Cantek Holdings, one of Israel's leaders in the medical cannabis field. Under the terms of the Agreement, Aurora will

Tilray ([[TLRY]] +15.4%) enters into privately negotiated exchange agreements with certain holders of its 5.00% Convertible Senior Notes due 2023. Pursuant to the exchange agreements, the company will exchange ~$72.9M in

Gainers: Sundial Growers (SNDL) +36%, DiaMedica Therapeutics (DMAC) +20%, Aurora Cannabis (ACB) +19%, Lyra Therapeutics (LYRA) +19%, Tilray (TLRY) +10%.Losers: Medigus (MDGS) -17%, Graybug Vision (GRAY) -14%, Immunic (IMUX) -13%, Arrowhead Pharmaceuticals (ARWR) -12%, Seres Therapeutics (MCRB) -10%.